Related Experiment Video

Updated: Jan 15, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.6K

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib

Brett King1, Amy McMichael2, Rodney Sinclair3

  • 1Dermatology Physicians of Connecticut, Fairfield, CT, USA.

Dermatology and Therapy
|October 14, 2025
PubMed
Abstract

Insights

This study evaluates a higher dose of ritlecitinib (100-mg QD) for severe alopecia areata (AA). The innovative design uses external controls, avoiding placebo randomization for enhanced alopecia areata treatment insights.

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Trials

Background:

  • Severe alopecia areata (AA) often shows limited response to current therapies.
  • Ritlecitinib (50-mg QD) is an approved JAK3/TEC inhibitor for severe AA.
  • A new trial investigates a higher ritlecitinib dose (100-mg QD) for improved efficacy.

Purpose of the Study:

  • To assess the efficacy and safety of ritlecitinib 100-mg QD in patients with severe AA.
  • To compare the 100-mg dose against external placebo and 50-mg dose arms.
  • To explore dose-response relationships and treatment outcomes in AA.

Main Methods:

  • Randomized, double-blind clinical trial (NCT06873945) in patients aged ≥12 years with ≥50% scalp hair loss.
  • Patients randomized to ritlecitinib 100-mg or 50-mg QD.
  • Innovative design using external placebo, synthetic placebo, and external nonresponder control groups.

Main Results:

  • Primary endpoint: SALT score ≤20 at week 24 for ritlecitinib 100-mg vs. external placebo.
  • Secondary endpoints include SALT score ≤20 at week 24/36 and change from baseline.
  • Analysis of week 48 outcomes for rerandomized nonresponders.

Conclusions:

  • The study aims to establish the efficacy of a higher ritlecitinib dose for severe AA.
  • Innovative trial design provides robust comparative data without placebo randomization.
  • Findings may inform optimized ritlecitinib dosing strategies for alopecia areata.
Keywords:
Alopecia areataExternal and synthetic control groupsJAK3Janus kinase 3Protein kinase inhibitorsResearch designRitlecitinibTEC kinases

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.4K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
406